William D. Hanley

2.4k total citations
39 papers, 1.7k citations indexed

About

William D. Hanley is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Infectious Diseases. According to data from OpenAlex, William D. Hanley has authored 39 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Radiology, Nuclear Medicine and Imaging, 9 papers in Molecular Biology and 8 papers in Infectious Diseases. Recurrent topics in William D. Hanley's work include Monoclonal and Polyclonal Antibodies Research (9 papers), HIV/AIDS drug development and treatment (8 papers) and Pharmacological Effects and Toxicity Studies (6 papers). William D. Hanley is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), HIV/AIDS drug development and treatment (8 papers) and Pharmacological Effects and Toxicity Studies (6 papers). William D. Hanley collaborates with scholars based in United States, Japan and China. William D. Hanley's co-authors include Κωνσταντίνος Κωνσταντόπουλος, Denis Wirtz, Robert Sackstein, Monica M. Burdick, Larissa Wenning, Marian Iwamoto, Julie A. Stone, John A. Wagner, Yiider Tseng and Owen J. T. McCarty and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

William D. Hanley

38 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William D. Hanley United States	20	485	415	408	379	275	39	1.7k
Hung Van Nguyen Vietnam	15	958 2.0×	243 0.6×	162 0.4×	100 0.3×	209 0.8×	56	1.8k
László Cervenak Hungary	29	526 1.1×	136 0.3×	122 0.3×	32 0.1×	164 0.6×	78	2.1k
Eric M. Billings United States	21	770 1.6×	86 0.2×	77 0.2×	26 0.1×	205 0.7×	28	1.8k
Frank Kolbinger Switzerland	25	648 1.3×	58 0.1×	385 0.9×	12 0.0×	195 0.7×	50	2.1k
Mary P. Andrich United States	16	429 0.9×	165 0.4×	73 0.2×	17 0.0×	544 2.0×	23	2.1k
Alexander Kozhich United States	16	355 0.7×	30 0.1×	230 0.6×	73 0.2×	125 0.5×	50	1.3k
Christiane Thallinger Austria	25	876 1.8×	66 0.2×	102 0.3×	29 0.1×	559 2.0×	56	1.7k
Eiji Sugiyama Japan	28	830 1.7×	100 0.2×	298 0.7×	15 0.0×	389 1.4×	136	2.5k
Joseph S. Friedberg United States	33	415 0.9×	43 0.1×	440 1.1×	96 0.3×	403 1.5×	135	3.5k
Wolfgang Hueber United States	23	992 2.0×	111 0.3×	980 2.4×	47 0.1×	341 1.2×	46	3.9k

Countries citing papers authored by William D. Hanley

Since Specialization

Citations

This map shows the geographic impact of William D. Hanley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William D. Hanley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William D. Hanley more than expected).

Fields of papers citing papers by William D. Hanley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William D. Hanley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William D. Hanley. The network helps show where William D. Hanley may publish in the future.

Co-authorship network of co-authors of William D. Hanley

This figure shows the co-authorship network connecting the top 25 collaborators of William D. Hanley. A scholar is included among the top collaborators of William D. Hanley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William D. Hanley. William D. Hanley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rizwan, Ahsan, Hugh Giovinazzo, Kun Wang, et al.. (2025). Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach. Clinical and Translational Science. 18(5). e70223–e70223.

Sahasranaman, Srikumar, Xianbin Tian, Ying Fei Li, et al.. (2025). Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact. Clinical and Translational Science. 18(5). e70221–e70221. 3 indexed citations

Demin, Oleg, et al.. (2025). Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies. CPT Pharmacometrics & Systems Pharmacology. 14(4). 706–717. 1 indexed citations

Tang, Mei, Amit Garg, Peter L. Bonate, et al.. (2024). Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors. Clinical Pharmacokinetics. 63(4). 423–438. 25 indexed citations

Passey, Chaitali, Jenna L. Voellinger, Leonid Gibiansky, et al.. (2023). Exposure‐safety and exposure‐efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors. CPT Pharmacometrics & Systems Pharmacology. 12(9). 1262–1273. 8 indexed citations

Chan, Phyllis, Jiajie Yu, Leslie W. Chinn, et al.. (2020). Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis. Pharmaceutical Research. 37(2). 25–25. 12 indexed citations

Deng, Rong, Mauricio Maia, Jeremy J. Lim, et al.. (2017). Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial. Clinical Pharmacokinetics. 57(3). 367–377. 22 indexed citations

Wang, Diane D., Yanke Yu, Nastya Kassir, et al.. (2017). The Utility of a Population Approach in Drug–Drug Interaction Assessments: A Simulation Evaluation. The Journal of Clinical Pharmacology. 57(10). 1268–1278. 7 indexed citations

Fayette, Jérôme, Lori J. Wirth, Cristina Oprean, et al.. (2016). Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Frontiers in Oncology. 6. 232–232. 84 indexed citations

10.

Le, Kha, Leonid Gibiansky, Menno van Lookeren Campagne, et al.. (2015). A Mechanistic Pharmacokinetic/Pharmacodynamic Model of Factor D Inhibition in Cynomolgus Monkeys by Lampalizumab for the Treatment of Geographic Atrophy. Journal of Pharmacology and Experimental Therapeutics. 355(2). 288–296. 24 indexed citations

11.

Wasfi, Yasmine, César Villarán, Celine Le Bailly De Tilleghem, et al.. (2011). The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma. Respiratory Medicine. 106(1). 34–46. 17 indexed citations

12.

Bernstein, Jonathan A., Nancy Liu, Barbara Knorr, et al.. (2010). MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respiratory Medicine. 105(3). 392–401. 26 indexed citations

13.

Anderson, Matt S., William D. Hanley, Bo Jin, et al.. (2010). Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. British Journal of Clinical Pharmacology. 71(4). 616–620. 18 indexed citations

14.

Anderson, Matt S., William D. Hanley, Bo Jin, et al.. (2010). Effect of Raltegravir on the Pharmacokinetics of Methadone. The Journal of Clinical Pharmacology. 50(12). 1461–1466. 8 indexed citations

15.

Iwamoto, Marian, Larissa Wenning, Bach‐Yen Nguyen, et al.. (2009). Effects of Omeprazole on Plasma Levels of Raltegravir. Clinical Infectious Diseases. 48(4). 489–492. 69 indexed citations

16.

Iwamoto, Marian, Kelem Kassahun, Matthew D. Troyer, et al.. (2007). Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation. The Journal of Clinical Pharmacology. 48(2). 209–214. 70 indexed citations

17.

Hanley, William D., Monica M. Burdick, Κωνσταντίνος Κωνσταντόπουλος, & Robert Sackstein. (2005). CD44 on LS174T Colon Carcinoma Cells Possesses E-Selectin Ligand Activity. Cancer Research. 65(13). 5812–5817. 113 indexed citations

18.

Κωνσταντόπουλος, Κωνσταντίνος, William D. Hanley, & Denis Wirtz. (2003). Receptor–ligand binding: ‘catch’ bonds finally caught. Current Biology. 13(15). R611–R613. 54 indexed citations

19.

Hanley, William D., Owen J. T. McCarty, Sameer Jadhav, et al.. (2003). Single Molecule Characterization of P-selectin/Ligand Binding. Journal of Biological Chemistry. 278(12). 10556–10561. 146 indexed citations

20.

Goel, Akshay, et al.. (1996). Coordination of Glycolysis and TCA Cycle Reaction Networks. Annals of the New York Academy of Sciences. 782(1). 1–16. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact